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Abstract
Introduction: Assessment of serum osteoprotegerin (OPG) concentrations in obese patients in comparison to healthy con-
trols and evaluation of a possible correlation between OPG and other markers of bone turnover or calcitropic hormones.
Material and methods: 50 obese perimenopausal women without concomitant diseases (BMI 36.7 – 4.1 kg/m†, mean age
50.4 – 4.9 yrs). The control group consisted of 19 healthy women (BMI 24.2 – 2.1 kg/m†; mean age 53.8 – 5.1 yrs).
In all patients serum concentration of OPG, C telopeptide of type I collagen containing the crosslinking site (CTX), oste-
ocalcin, parathormone (PTH) and vitamin D (25-OH-D3) was assessed. Dual energy x-ray absorptiometry (the DXA me-
thod) of the lumbar spine and femoral neck was performed using a Lunar DPXL to measure bone marrow density (BMD).
Results: In obese perimenopausal women serum OPG, osteocalcin and 25-OH-D3 levels were significantly lower, and the
serum PTH level was significantly higher in comparison to healthy controls. A significantly positive correlation was found
between serum OPG level and age in both obese and control subjects.
Conclusion: The serum OPG level in obese perimenopausal women is significantly lower in comparison to healthy con-
trols and does not correlate significantly with biochemical markers of bone turnover, calcitropic hormones and BMD.
It probably cannot play a protective role in the pathogenesis of bone loss in obese perimenopausal women.
(Pol J Endocrinol 2007; (58) 1: 710)
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Streszczenie
WstŒp: Celem niniejszej pracy by‡a ocena stŒ¿enia osteoprotegeryny (OPG) w surowicy oty‡ych pacjentek w porównaniu
z grup„ kontroln„ oraz próba wykazania ewentualnych powi„zaæ osteoprotegeryny ze wskanikami obrotu kostnego
oraz hormonami kalcitropowymi.
Materia‡ i metody: 50 kobiet w wieku oko‡omenopauzalnym z oty‡oci„ prost„ bez chorób towarzysz„cych (BMI 36,7 – 4,1 kg/m†,
wiek 50,4 – 4,9 roku). GrupŒ kontroln„ stanowi‡o 19 zdrowych kobiet (BMI 24,2 – 2,1 kg/m†; wiek 53,8 – 5,1 lat).
U wszystkich badanych oznaczono w surowicy stŒ¿enia OPG, C-koæcowego usieciowanego telopeptydu kolagenu typu I
(CTX), osteokalcyny, parathormonu (PTH) oraz 25-OH-D3. Badanie gŒstoci mineralnej koci (BMD, bone mineral density)
w obrŒbie odcinka lŒdwiowego krŒgos‡upa oraz szyjki koci udowej wykonano metod„ absorpcjometrii podwójnej ener-
gii promieniowania rentgenowskiego (DXA, Dual Energy X-ray Absorptiometry) przy u¿yciu aparatu Lunar DPXL.
Wyniki: W grupie oty‡ych chorych obserwowano znamiennie ni¿sze stŒ¿enie OPG, osteokalcyny i 25-OH-D3 oraz zna-
miennie wy¿sze stŒ¿enie PTH w porównaniu z grup„ kontroln„. Zarówno w grupie badanej, jak i w grupie kontrolnej
zaobserwowano dodatni„ korelacjŒ pomiŒdzy stŒ¿eniem OPG a wiekiem pacjentek.
Wnioski: U oty‡ych kobiet w wieku oko‡omenopauzalnym stŒ¿enie osteoprotegeryny w surowicy krwi jest znamiennie
ni¿sze w porównaniu z grup„ kontroln„ i nie koreluje ze wskanikami obrotu kostnego, hormonami kalcitropowymi ani
z BMD. Osteoprotegeryna prawdopodobie nie spe‡nia  funkcji ochronnej w patogenezie ubytku masy kostnej u oty‡ych
kobiet w wieku oko‡omenopauzalnym.
(Endokrynol Pol 2007; (58) 1: 710)
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Introduction
Obesity in women is associated with a lower risk of oste-
oporosis, probably because of the beneficial effect of
hyperoestrogaenemia [1]. When obese women were
compared with lean ones of the same age, thinness was
found to be an important risk factor for low bone mass
and increased bone loss in postmenopausal women [2].
Osteoprotegerin (OPG) was identified as a member
of the tumour necrosis factor (TNF) receptor superfa-
mily that acts as an inhibitor of osteoclastogenesis [3].
The biological effects of OPG on bone cells are: inhibi-
tion of the terminal stages of osteoclast differentiation
[4], suppression of the activation of the mature osteoc-
last [5] and induction of apoptosis [6]. Additionally
OPG antagonises the induction of bone resorption by
1.25 (OH)2-D3 and parathormone (PTH) [7].
The aim of the study was to assess serum OPG con-
centration in obese patients in comparison to healthy
controls. An answer was sought to the question of whe-
ther and to what extent serum OPG is a potent protec-
tive factor for bone loss in obese perimenopausal wo-
men. Secondly we aimed to evaluate the relationship
between serum OPG level and both markers of bone
turnover and calcitropic hormones.
Materials and methods
Fifty obese perimenopausal women (BMI 36.7 – 4.1 kg/m†,
mean age 50.4 – 4.9 yrs) were enrolled into the study.
All were diagnosed with simple obesity without conco-
mitant diseases. None had undergone ovariectomy. All
subjects were informed about the nature of the study
and signed forms giving their informed consent. The
exclusion criteria included evidence of present or re-
cent (during the preceding 3 months) infectious dise-
ase, drug therapy, cigarette smoking and alcohol con-
sumption of more than two drinks a week. The control
group consisted of 19 lean healthy women without con-
comitant diseases (BMI 24.2 – 2.1 kg/m†; mean age 53.8 –
– 5.1 yrs).
Body weight and height were measured and BMI
values were calculated. Blood samples were withdrawn
from each subject between 8.00 and 9.00 am after an
overnight fast. After clot formation the samples were
centrifuged (1000 × G) at room temperature for 10 min.
The serum obtained was drawn into plastic tubes and
stored at 80°C until the time of the assay.
Serum concentrations of OPG, CTX, osteocalcin,
PTH and 25-OH-D3 were assessed for all patients. OPG
was estimated using ELISA (BioVentor, Czech Repu-
blic). The Electrochemiluminescent ImmunoAssay
ECLIA (Roche, France) was used for osteocalcin, the C
telopeptide of type I collagen containing the crosslin-
king site (CTX) and PTH assay. 25-(OH)-D3 was measu-
red by a RIA (The Bio Source, Belgium).
Dual energy x-ray absorptiometry (the DXA me-
thod) of the lumbar spine and femoral neck was per-
formed using a Lunar DPXL to measure bone mineral
density (BMD). All text and table values are expressed
as means – S.D. All statistical analyses were performed
using the STATISTICA computer program. The results
were analysed using the Kolmogorov-Smirnoff test and
Spearmans correlation analysis. P values < 0.05 were
considered to be statistically significant.
Results
In obese perimenopausal women serum OPG, osteocal-
cin and 25-OH-D3 levels are significantly lower and PTH
serum levels significantly higher in comparison to he-
althy controls. BMD of the lumbar spine and femoral
neck were significantly higher in obese women in com-
parison to healthy controls (Table I)
Table I
Serum concentration of osteoprotegerin, biochemical markers of bone turnover, calcitropic hormones and BMD in 50 obese
subjects in comparison to 19 healthy controls (means – SD)
Tabela I
StŒ¿enie osteoprotegeryny, biochemicznych wskaników obrotu kostnego, hormonów kalcitropowych oraz BMD u 50 oty‡ych
chorych w porównaniu z grup„ kontroln„ (rednia – SD)
Subjects Controls p
Osteoprotegerin [pmol/l] 4.39–1.39 5.58–0.53 < 0.005
PTH [pg/ml] 50.6–15.6 36.6–19.8 p < 0.01
25-OH-D3 [ng/ml] 28.7–14.7 40.2–18.7 p < 0.001
CTX [ng/ml] 0.3–0.2 0.3–0.1 ns
Osteocalcin [ng/ml] 21.2–8.4 28.1–12.5 p < 0.005
BMD neck [g/cm2] 1.07–0.16 0.85–0.11 p < 0.001
BMD L1L4 [g/cm
2] 1.24–0.17 1.07–0.13 p < 0.05
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The OPG serum level is positively correlated with
age in both obese subjects and controls (r = 0.28, p = 0.048;
r = 0.5. p = 0.03; respectively).
Discussion
A large number of hormones, cytokines, growth and
inflammatory factors are responsible for regulation of
bone metabolism. In OPG a further factor has now been
recognised that influences osteoclast formation and
activity.
RANKL (osteoclast differentiation factor) is produ-
ced by an osteoblastic lineage cell and stimulates its re-
ceptor RANK, which is located on the osteoclast [8]. The
effect of RANKL/RANK interaction is enhanced diffe-
rentiation, fusion and activation of osteoclasts [7]. Oste-
oprotegerin (or OCIF, osteoclastogenesis inhibitory fac-
tor), acts as a decoy receptor that neutralises RANKL,
binding to it and blocking its interaction with RANK,
thus inhibiting osteoclast differentiation [3].
There are many factors influencing OPG/RANKL/
/RANK production, including PTH, calcitriol, glucocor-
ticosteroids, IL-1 and PGE-2. These can either inhibit
(PTH, steroids) or stimulate (oestrogen, TGF-B) OPG
production [3].
The purpose of the present study was to evaluate
whether and to what extent OPG may influence or be
responsible for higher bone mass in obese women. We
have observed lower serum OPG levels in obese sub-
jects in comparison to healthy controls. Our specula-
tion that higher BMD in the obese may be associated
with higher OPG serum levels turned out to be wrong.
Moreover, we did not find any significant correlation
between BMD and serum OPG levels either in obese
women or in controls. We cannot find any reasonable
explanation for this phenomenon. Lower serum OPG
levels may be caused by the higher serum PTH level
(that is observed in the obese) as PTH may decrease
OPG production [9]. Andersen and Mosekilde et al. [10, 11]
showed that PTH concentration is dependent on the
degree of obesity. The finding that serum PTH concen-
tration and the expression of OPG in human bone tis-
sue are inversely correlated was reported in postmeno-
pausal women by Seck et al. [12]. On the other hand,
obese patients are characterised by higher oestrogen
levels, which may stimulate OPG production.
The finding of lower 25-OH-D3 in obese patients is
not new. The low level of 25-hydroxyvitamin D3 in obese
subjects may be caused by the decreased exposure to
sunlight (limited mobility of obese patients) [13], exces-
sive storage of vitamin D in adipose tissue [11] and in-
hibition of its synthesis in liver by the increased level of
1,25-dihydroxyvitamin D [14].
Both lower osteocalcin and OPG levels may be con-
nected with lower activity of bone metabolism in obese
women and less compensating production of OPG in
this group of patients.
In the present study we did not find any significant
correlation between serum OPG concentration and
markers of bone turnover, OPG and calcitropic hormo-
nes or between OPG and BMD. A positive correlation
was found between OPG and age in both obese sub-
jects and controls.
Other authors, who did not evaluate OPG serum
levels in obesity, found a negative correlation between
OPG and BMD, a positive correlation with biochemical
markers of bone turnover [15], no significant correla-
tion between OPG and markers of bone turnover [16]
or a confirmed negative correlation between serum
OPG concentrations and BMD in postmenopausal wo-
men [17], with no convergence of these findings.
Our findings, when analysed, came as a surprise in
view of the established protective effect of OPG on bone.
There are many other factors responsible for bone meta-
bolism (excluding cytokines, drugs and hormonal axis)
such as diet and physical activity, and so we cannot exc-
lude their influence on our results. We hope that further
investigations, including research into the influence of
weight reduction therapy on OPG serum levels in obese
women, will provide a satisfactory explanation.
Conclusion
Serum osteoprotegerin concentration in obese perime-
nopausal women is significantly lower in comparison
to healthy controls and does not correlate significantly
either with biochemical markers of bone turnover, cal-
citropic hormones or bone mineral density. It probably
cannot play a protective role in the pathogenesis of bone
loss in obese perimenopausal women.
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